Platform to try new treatments for progressive supranuclear palsy
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP)
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11160498
This project will compare three medicines for people with mild to moderate progressive supranuclear palsy to learn if they are safe and help symptoms.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11160498 on ClinicalTrials.gov |
What this research studies
You would join a multicenter, randomized trial that assigns people to one of three tau-targeting or neuroprotective medicines or to a shared placebo group. Each treatment will be taken and followed for about 12 months while doctors track safety and changes using a modified PSP Rating Scale (mPSPRS-15) and other clinical measures. The platform design shares a common protocol and placebo information so more treatments can be tested faster and with fewer patients overall. The project will also look for biological markers that might help detect benefit or predict who responds.
Who could benefit from this research
Good fit: Ideal candidates are people with mild to moderate progressive supranuclear palsy who meet the study’s medical criteria and can attend regular visits for about a year.
Not a fit: People with very advanced PSP, other major neurological diseases, or those unable to commit to study visits or procedures may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this could identify an effective and safe therapy that slows symptoms or progression of PSP and speed access to more treatment options.
How similar studies have performed: Platform trials have helped speed testing in other neurodegenerative diseases, though tau-targeting treatments for PSP remain largely unproven to date.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOXER, ADAM L. — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: BOXER, ADAM L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Amyotrophic Lateral Sclerosis Motor Neuron Disease